Epithelial cell-derived cytokines CST3 and GDF15 as potential therapeutics for pulmonary fibrosis

[1]  A. Hajari Case,et al.  Clinical use of nintedanib in patients with idiopathic pulmonary fibrosis , 2017, BMJ Open Respiratory Research.

[2]  K. Meyer,et al.  Role of pirfenidone in the management of pulmonary fibrosis , 2017, Therapeutics and clinical risk management.

[3]  A. Kaneda,et al.  Combined Secretomics and Transcriptomics Revealed Cancer-Derived GDF15 is Involved in Diffuse-Type Gastric Cancer Progression and Fibroblast Activation , 2016, Scientific Reports.

[4]  M. Nakazato,et al.  Breakdown of Epithelial Barrier Integrity and Overdrive Activation of Alveolar Epithelial Cells in the Pathogenesis of Acute Respiratory Distress Syndrome and Lung Fibrosis , 2015, BioMed research international.

[5]  K. Tsui,et al.  Growth differentiation factor-15: a p53- and demethylation-upregulating gene represses cell proliferation, invasion, and tumorigenesis in bladder carcinoma cells , 2015, Scientific Reports.

[6]  C. Ruppert,et al.  Compromised peroxisomes in idiopathic pulmonary fibrosis, a vicious cycle inducing a higher fibrotic response via TGF-β signaling , 2015, Proceedings of the National Academy of Sciences.

[7]  Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. , 2015, The New England journal of medicine.

[8]  Chun Xing Li,et al.  Treatment with CA-074Me, a Cathepsin B inhibitor, reduces lung interstitial inflammation and fibrosis in a rat model of polymyositis , 2014, Laboratory Investigation.

[9]  H. Collard,et al.  Design of the INPULSIS™ trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis. , 2014, Respiratory medicine.

[10]  S. Marchand-Adam,et al.  Regulation of TGF-β1-driven Differentiation of Human Lung Fibroblasts , 2014, The Journal of Biological Chemistry.

[11]  S. Rosselot.  Idiopathic pulmonary fibrosis. , 2014, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[12]  M. Syamsunarno,et al.  Deranged fatty acid composition causes pulmonary fibrosis in Elovl6-deficient mice , 2013, Nature Communications.

[13]  S. Friedman,et al.  Therapy for Fibrotic Diseases: Nearing the Starting Line , 2013, Science Translational Medicine.

[14]  T. Meuten,et al.  WNT7B in fibroblastic foci of idiopathic pulmonary fibrosis , 2012, Respiratory Research.

[15]  Y. Yamaguchi,et al.  A Peptide Derived from Endostatin Ameliorates Organ Fibrosis , 2012, Science Translational Medicine.

[16]  Jong-Wha Jung,et al.  Design, synthesis and insight into the structure-activity relationship of 1,3-disubstituted indazoles as novel HIF-1 inhibitors. , 2011, Bioorganic & Medicinal Chemistry Letters.

[17]  R. D. du Bois,et al.  Pirfenidone in idiopathic pulmonary fibrosis: the CAPACITY program , 2011, Expert review of respiratory medicine.

[18]  D. Fairclough,et al.  Pirfenidone in idiopathic pulmonary fibrosis , 2010, European Respiratory Journal.

[19]  T. Chou.  Drug combination studies and their synergy quantification using the Chou-Talalay method. , 2010, Cancer research.

[20]  G. Raghu,et al.  Pirfenidone in idiopathic pulmonary fibrosis , 2009, European Respiratory Journal.

[21]  S. Sahn,et al.  Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial , 2009, The Lancet.

[22]  F. Hilberg,et al.  Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120). , 2009, Journal of medicinal chemistry.

[23]  A. Moles,et al.  Cathepsins B and D drive hepatic stellate cell proliferation and promote their fibrogenic potential , 2009, Hepatology.

[24]  H. Bolte,et al.  Standardized quantification of pulmonary fibrosis in histological samples. , 2008, BioTechniques.

[25]  D. Warburton,et al.  The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? , 2008, The international journal of biochemistry & cell biology.

[26]  G. Amir,et al.  Epithelial cell apoptosis by fas ligand-positive myofibroblasts in lung fibrosis. , 2007, American journal of respiratory cell and molecular biology.

[27]  A. Schnapp,et al.  Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model. , 2006, American journal of respiratory and critical care medicine.

[28]  R. Lotan,et al.  Induction of GDF-15/NAG-1/MIC-1 in human lung carcinoma cells by retinoid-related molecules and assessment of Its role in apoptosis , 2006, Cancer Biology & Therapy.

[29]  Katsutoshi Nakayama,et al.  Anticoagulant therapy for idiopathic pulmonary fibrosis. , 2005, Chest.

[30]  W. Schiemann,et al.  The use of cystatin C to inhibit epithelial–mesenchymal transition and morphological transformation stimulated by transforming growth factor-β , 2005, Breast Cancer Research.

[31]  Mehdi Ahmadi,et al.  Evaluation of EM and orthopedic residents' pain estimation about patients with limb trauma who were visited in the Emergency Department of Hazrat Rasoul Hospital , 2005 .

[32]  P. Villa,et al.  Serum cystatin C concentration as a marker of acute renal dysfunction in critically ill patients , 2005, Critical care.

[33]  W. Schiemann,et al.  Cystatin C antagonizes transforming growth factor beta signaling in normal and cancer cells. , 2004, Molecular cancer research : MCR.

[34]  J. Zaunders,et al.  Macrophage inhibitory cytokine 1 reduces cell adhesion and induces apoptosis in prostate cancer cells. , 2003, Cancer research.

[35]  G. Gores,et al.  Cathepsin B inactivation attenuates hepatic injury and fibrosis during cholestasis. , 2003, The Journal of clinical investigation.

[36]  G. Gabbiani,et al.  The myofibroblast in wound healing and fibrocontractive diseases , 2003, The Journal of pathology.

[37]  W. Thurlbeck,et al.  Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality. , 2001, American journal of respiratory and critical care medicine.

[38]  K. Flaherty,et al.  Corticosteroids in idiopathic pulmonary fibrosis , 2001, Current opinion in pulmonary medicine.

[39]  B. Kobilka,et al.  Functional differences between full and partial agonists: evidence for ligand-specific receptor conformations. , 2001, The Journal of pharmacology and experimental therapeutics.

[40]  G. Raghu,et al.  Treatment of Idiopathic Pulmonary Fibrosis with a New Antifibrotic Agent , Pirfenidone Results of a Prospective , Open-label Phase II Study , 1999 .

[41]  S. Swensen,et al.  Colchicine versus prednisone in the treatment of idiopathic pulmonary fibrosis. A randomized prospective study. Members of the Lung Study Group. , 1998, American journal of respiratory and critical care medicine.

[42]  T. Urano,et al.  Tissue factor expression and fibrin deposition in the lungs of patients with idiopathic pulmonary fibrosis and systemic sclerosis. , 1997, American journal of respiratory and critical care medicine.

[43]  G. Raghu,et al.  Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. , 1991, The American review of respiratory disease.